Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 228

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 228
---
/14/2031 |
|                                              |     |           | 85,922,000 | -2 |     |            | 7/10/2024 |     |          | 0.003 |     |            | 7/10/2034 |
| All senior management as a group (2 persons) |     |           | 85,958,813 | -4 |     |            |        -5 |     |          |    -6 |     |            |        -7 |

_________

| (1) | Of these options, 375 previously vested on September 9, 2020, and the remaining 1,125 options have subsequently 
 vested, or will vest, in 12 equal quarterly tranches, over a subsequent three-year period.                      |

| (2) | Of these options, 25% of the options vest 12 months after the grant date, and the remaining options have 
 subsequently vested, or will vest, in 12 equal quarterly tranches over a subsequent three-year period.   |

| (3) | All of Dr. Zamoryakhin have expired. |

| (4) | 36,813 stock options are fully vested. |

| (5) | The grant dates range from September 9, 2019 to July 10, 2024. |

| (6) | The exercise price of the options range from £0.003 to £5.55. |

| (7) | The stock options expire between September 9, 2029 and July 10, 2034. |

| 112 |

Agreements with Senior Management

Stephen Stamp. On September
9, 2019, we entered into a service agreement, or the Service Agreement, with Mr. Stamp. The Service Agreement provides for a base salary,
incentive compensation benefits, and, in certain circumstances, severance benefits. The Service Agreement may be terminated, subject to
certain exceptions, upon six months’ prior notice.

The Service Agreement provides
for an initial base salary of £160,000. Mr. Stamp’s base salary is subject to increase each April 1 by the percentage increase,
if any, in the “All Items Index of Retail Prices” published by the United Kingdom Office for National Statistics over the
previous year. The base salary of Mr. Stamp is to be reviewed annually to consider any increase in salary. Mr. Stamp’s base salary
was increased to £230,000 effective as of